{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:23:40Z","timestamp":1772166220586,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Some patients with systemic juvenile idiopathic arthritis (SJIA) and severe, refractory disease achieved remission through intensive immunosuppressive treatment followed by autologous hematopoietic stem cell transplantation (HSCT). However, disease relapsed in most cases. More recently selected SJIA patients received allogenic HSCT from a HLA-identical sibling or a HLA matched unrelated donor. While most transplanted patients achieved sustained SJIA remission off-treatment, the procedure-related morbidity was high.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>A girl presented SJIA with a severe disease course since the age of 15\u2009months. She was refractory to the combination of methotrexate and steroids to anti-interleukin (IL)-1, then anti-IL-6, tumor necrosis factor alpha inhibitors, and thalidomide. Given the high disease burden and important treatment-related toxicity the indication for a haploidentical HSCT from her mother was validated, as no HLA matched donor was available. The patient received a T replete bone marrow graft at the age of 3.7\u2009years. Conditioning regimen contained Rituximab, Alemtuzumab, Busulfan, and Fludarabine. Cyclophosphamide at D\u2009+\u20093 and\u2009+\u20094 post HSCT was used for graft-versus-host-disease prophylaxis, followed by Cyclosporin A and Mycophenolate Mofetil. Post HSCT complications included severe infections, grade 3 intestinal graft-versus-host-disease, autoimmune thyroiditis, and immune thrombocytopenia. Three years after HSCT, the child is alive and well, notwithstanding persistent hypothyroidy requiring substitution. Immune thrombocytopenia had resolved. Most importantly, SJIA was in complete remission, off immunosuppressive drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Allogenic HSCT may be a therapeutic option, even with a HLA haplo-identical alternative donor, in patients with inflammatory diseases such as SJIA. Despite increased experience with this treatment, the risk of life-threatening complications restrains its indication to selected patients with severe, refractory disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-021-00523-3","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T07:06:50Z","timestamp":1615532810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Sustained remission after haploidentical bone marrow transplantation in a child with refractory systemic juvenile idiopathic arthritis"],"prefix":"10.1186","volume":"19","author":[{"given":"Guillaume","family":"Morelle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Castelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graziella","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Breton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Bendavid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Boussard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Mouy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Bader-Meunier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Semeraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Faye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Cavazzana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9n\u00e9dicte","family":"Neven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Blanche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1769-549X","authenticated-orcid":false,"given":"Pierre","family":"Quartier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Despina","family":"Moshous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"issue":"9","key":"523_CR1","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.autrev.2016.07.004","volume":"15","author":"R Cimaz","year":"2016","unstructured":"Cimaz R. Systemic-onset juvenile idiopathic arthritis. Autoimmun Rev sept. 2016;15(9):931\u20134.","journal-title":"Autoimmun Rev sept"},{"key":"523_CR2","doi-asserted-by":"crossref","unstructured":"Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998\u20131006.","DOI":"10.1016\/S0140-6736(08)60454-7"},{"issue":"5","key":"523_CR3","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"P Quartier","year":"2011","unstructured":"Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747\u201354.","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"523_CR4","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396\u2013406.","journal-title":"N Engl J Med"},{"issue":"25","key":"523_CR5","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. N Engl J Med. 2012;367(25):2385\u201395.","journal-title":"N Engl J Med"},{"issue":"12","key":"523_CR6","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1136\/annrheumdis-2019-216040","volume":"78","author":"VE Saper","year":"2019","unstructured":"Saper VE, Chen G, Deutsch GH, Guillerman RP, Birgmeier J, Jagadeesh K, et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis. 2019;78(12):1722\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"523_CR7","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1002\/art.41073","volume":"71","author":"GS Schulert","year":"2019","unstructured":"Schulert GS, Yasin S, Carey B, Chalk C, Do T, Schapiro AH, et al. Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors. Arthritis Rheumatol. 2019;71(11):1943\u201354.","journal-title":"Arthritis Rheumatol"},{"issue":"9167","key":"523_CR8","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/S0140-6736(05)75094-7","volume":"353","author":"P Quartier","year":"1999","unstructured":"Quartier P, Prieur AM, Fischer A. Haemopoietic stem-cell transplantation for juvenile chronic arthritis. Lancet Lond Engl. 1999;353(9167):1885\u20136.","journal-title":"Lancet Lond Engl"},{"issue":"12","key":"523_CR9","first-page":"720","volume":"45","author":"M Mistr\u00edk","year":"1999","unstructured":"Mistr\u00edk M, Bojt\u00e1rov\u00e1 E, Feh\u00e9rv\u00edzyov\u00e1 E, Hrubisko M, Rovensk\u00fd J, Luk\u00e1c J, et al. Autologous stem cell transplantation in a patient with juvenile chronic arthritis. Vnitr Lek. 1999;45(12):720\u20132.","journal-title":"Vnitr Lek"},{"issue":"7","key":"523_CR10","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1002\/art.22656","volume":"56","author":"DMC Brinkman","year":"2007","unstructured":"Brinkman DMC, de Kleer IM, ten Cate R, van Rossum MAJ, Bekkering WP, Fasth A, et al. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term followup of a prospective clinical trial. Arthritis Rheum. 2007;56(7):2410\u201321.","journal-title":"Arthritis Rheum"},{"issue":"9152","key":"523_CR11","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/S0140-6736(98)05399-9","volume":"353","author":"N Wulffraat","year":"1999","unstructured":"Wulffraat N, van Royen A, Bierings M, Vossen J, Kuis W. Autologous haemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis. Lancet. 1999;353(9152):550\u20133.","journal-title":"Lancet"},{"issue":"1","key":"523_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.molimm.2008.12.029","volume":"47","author":"M Abinun","year":"2009","unstructured":"Abinun M, Flood TJ, Cant AJ, Veys P, Gennery AR, Foster HE, et al. Autologous T cell depleted haematopoietic stem cell transplantation in children with severe juvenile idiopathic arthritis in the UK (2000\u20132007). Mol Immunol. 2009;47(1):46\u201351.","journal-title":"Mol Immunol"},{"issue":"7","key":"523_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1182\/bloodadvances.2017014449","volume":"2","author":"JMF Silva","year":"2018","unstructured":"Silva JMF, Ladomenou F, Carpenter B, Chandra S, Sedlacek P, Formankova R, et al. Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis. Blood Adv. 2018;2(7):777\u201386.","journal-title":"Blood Adv"},{"issue":"12","key":"523_CR14","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41584-019-0306-7","volume":"15","author":"KM Sullivan","year":"2019","unstructured":"Sullivan KM, Sarantopoulos S. Allogeneic HSCT for autoimmune disease: a shared decision. Nat Rev Rheumatol. 2019;15(12):701\u20132.","journal-title":"Nat Rev Rheumatol"},{"key":"523_CR15","doi-asserted-by":"crossref","unstructured":"Greco R, Labopin M, Badoglio M, Veys P, Furtado Silva JM, Abinun M, et al. Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties. Front Immunol [Internet]. 2019 [cit\u00e9 17 mai 2020];10. Disponible sur: https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2019.01570\/full.","DOI":"10.3389\/fimmu.2019.01570"},{"issue":"7","key":"523_CR16","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.bbmt.2019.03.009","volume":"25","author":"B Neven","year":"2019","unstructured":"Neven B, Diana J-S, Castelle M, Magnani A, Rosain J, Touzot F, et al. Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for primary Immunodeficiencies and inherited disorders in children. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2019;25(7):1363\u201373.","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00523-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12969-021-00523-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00523-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T07:15:02Z","timestamp":1615533302000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-021-00523-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["523"],"URL":"https:\/\/doi.org\/10.1186\/s12969-021-00523-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-89163\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-89163\/v2","asserted-by":"object"}]},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"assertion":[{"value":"6 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Both parents gave their written informed consent for the procedure, which was approved by the ethics committee of our institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}